Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab.
Клиническое исследование II фазыСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Horndalsveen Henrik, Haakensen Vilde Drageset, Madebo Tesfaye, Grønberg Bjørn Henning, Halvorsen Tarje Onsøien, Bjaanæs Maria Moksnes, Danielsen Britina Kjuul, Børve Mari, Kokkvoll Solveig, Boda Tonje Sofie Dalen, Öjlert Åsa Kristina, Helland Åslaug
Аннотация
INTRODUCTION: The benefit of durvalumab after chemoradiotherapy (CRT) varies widely in unresectable stage III NSCLC. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection may help identify patients at high risk of early treatment failure during and after durvalumab.
METHODS: In this prospective multicenter study, patients with unresectable stage III NSCLC received CRT followed by durvalumab. Plasma samples were collected at screening, after CRT, at predefined time points during durvalumab, and during post-treatment follow-up. A tumor-agnostic, hybrid-capture ctDNA MRD assay personalized to each patient classified samples as ctDNA detected (MRD positive) or not detected (MRD negative).
RESULTS: A total of 659 plasma samples from 84 patients were analyzed. Detectable ctDNA before the seventh cycle of durvalumab (after 6 mo of treatment) and 3 months after treatment completion was strongly associated with inferior progression-free survival (PFS) (hazard ratio [HR]: 2.45, 95% confidence interval [CI]: 1.18-5.11, p = 0.013 and HR: 5.37, 95% CI: 1.93-14.93, p < 0.001, respectively). Detection of ctDNA after CRT but before durvalumab initiation was not prognostic (HR: 1.38, 95% CI: 0.78-2.41, p = 0.269). In a multivariable time-dependent Cox model incorporating all post-CRT samples, detectable ctDNA was associated with a nearly threefold higher risk of progression (HR: 2.95, 95% CI: 1.69-5.15, p < 0.001).
CONCLUSIONS: Detectable ctDNA during and after durvalumab was associated with markedly shorter PFS in unresectable stage III NSCLC. Serial ctDNA-based MRD assessment may help identify patients at high risk of relapse who could benefit from alternative or intensified treatment strategies, ideally within prospective clinical trials.
GOV IDENTIFIER: NCT04392505.
METHODS: In this prospective multicenter study, patients with unresectable stage III NSCLC received CRT followed by durvalumab. Plasma samples were collected at screening, after CRT, at predefined time points during durvalumab, and during post-treatment follow-up. A tumor-agnostic, hybrid-capture ctDNA MRD assay personalized to each patient classified samples as ctDNA detected (MRD positive) or not detected (MRD negative).
RESULTS: A total of 659 plasma samples from 84 patients were analyzed. Detectable ctDNA before the seventh cycle of durvalumab (after 6 mo of treatment) and 3 months after treatment completion was strongly associated with inferior progression-free survival (PFS) (hazard ratio [HR]: 2.45, 95% confidence interval [CI]: 1.18-5.11, p = 0.013 and HR: 5.37, 95% CI: 1.93-14.93, p < 0.001, respectively). Detection of ctDNA after CRT but before durvalumab initiation was not prognostic (HR: 1.38, 95% CI: 0.78-2.41, p = 0.269). In a multivariable time-dependent Cox model incorporating all post-CRT samples, detectable ctDNA was associated with a nearly threefold higher risk of progression (HR: 2.95, 95% CI: 1.69-5.15, p < 0.001).
CONCLUSIONS: Detectable ctDNA during and after durvalumab was associated with markedly shorter PFS in unresectable stage III NSCLC. Serial ctDNA-based MRD assessment may help identify patients at high risk of relapse who could benefit from alternative or intensified treatment strategies, ideally within prospective clinical trials.
GOV IDENTIFIER: NCT04392505.